ALK and non-small cell lung carcinoma: This pattern aligns with results of the ALINA trial, which demonstrated that adjuvant alectinib significantly improved disease-free survival versus platinum-based chemotherapy in resected Stage IB–IIIA ALK-positive NSCLC (hazard ratio, 0.24; 95% CI, 0.13%–0.45%; p = 0.001).6) Although ALINA evaluated planned adjuvant therapy, its findings support the strategy of continuing ALK inhibition after salvage surgery.